CONMED Corporation
CNMD · NYSE
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.94 | -0.50 | 0.18 |
| FCF Yield | 1.45% | 2.02% | 1.86% | 2.15% |
| EV / EBITDA | 43.68 | 79.72 | 42.45 | 37.30 |
| Quality | ||||
| ROIC | 1.34% | 0.62% | 2.00% | 2.80% |
| Gross Margin | 55.01% | 55.33% | 57.58% | 56.52% |
| Cash Conversion Ratio | 18.78 | 1.36 | 6.88 | 1.28 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.86% | 5.20% | 6.20% | 7.73% |
| Free Cash Flow Growth | -38.01% | -3.93% | -17.76% | 20.31% |
| Safety | ||||
| Net Debt / EBITDA | 15.06 | 25.04 | 12.50 | 10.78 |
| Interest Coverage | 4.88 | 1.93 | 5.93 | 7.10 |
| Efficiency | ||||
| Inventory Turnover | 0.43 | 0.40 | 0.43 | 0.40 |
| Cash Conversion Cycle | 214.18 | 224.36 | 210.56 | 221.25 |